STOCK TITAN

HEMOGENYX PHARMACEUTICALS - HOPHF STOCK NEWS

Welcome to our dedicated page for HEMOGENYX PHARMACEUTICALS news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on HEMOGENYX PHARMACEUTICALS stock.

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is a biopharmaceutical group focused on developing new therapies and treatments for blood diseases. The company's Chimeric Bait Receptor platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors. Hemogenyx Pharmaceuticals utilizes Artificial Intelligence for protein structure simulations and mRNA synthesis to expedite R&D efforts. With recent FDA consents for Phase I trials of HEMO-CAR-T for AML, the company is advancing towards potentially life-saving treatments.

Rhea-AI Summary

Dr. Alan E. Walts has joined Hemogenyx Pharmaceuticals as a Board observer and business advisor, bringing over 25 years of biopharmaceutical experience. His background includes significant roles at Genzyme and various biotechnology firms. Dr. Walts' expertise is expected to accelerate Hemogenyx's development pipeline, particularly in new therapies for blood diseases. CEO Dr. Vladislav Sandler expressed optimism about Dr. Walts' addition, noting its potential to enhance the company’s strategic direction and R&D efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals has released a new corporate presentation detailing its work in developing innovative therapies for deadly blood diseases. The company, based in London with operations in New York City, focuses on advancing treatments for conditions like leukemia, lymphoma, and severe autoimmune diseases. With over 50 years of experience in bone marrow transplantation, Hemogenyx aims to improve patient outcomes and broaden access to these life-saving procedures. The presentation can be accessed here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals (OTC PINK:HOPHF) announced the successful passing of all resolutions at its Annual General Meeting (AGM) held on June 25, 2021. Key resolutions included the approval of the 2020 Annual Report and Accounts with 99.87% votes in favor, and the Directors' Remuneration Policy which received 99.07% approval. The total votes cast amounted to 126,796,363, representing 12.94% of the issued share capital. The AGM's outcomes reflect strong shareholder support for the management's proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Hemogenyx Pharmaceuticals has announced that its Annual General Meeting (AGM) on June 25, 2021, will be a closed meeting due to COVID-19 restrictions in the UK. Only two specified Shareholders will attend to ensure quorum. Other Shareholders are encouraged to vote by proxy, appointing 'the Chair of the AGM.' While remote access will be provided for Shareholders to observe, they cannot vote electronically. The voting will occur via a poll to acknowledge proxy votes, with results published shortly after the AGM.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals has reported that as of May 28, 2021, its total issued share capital stands at 979,749,321 ordinary shares of 1 pence each, with no shares held in treasury. This figure represents the total number of voting rights in the company. Shareholders are advised to use this number as a denominator for any calculations regarding their investment obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.73%
Tags
none
Rhea-AI Summary

Hemogenyx Pharmaceuticals has announced the admission of 433,333,333 new Ordinary Shares to the London Stock Exchange as part of the termination of a convertible loan note facility with Mint Capital Advisors. The company confirms that no convertible loan notes remain outstanding and will continue progressing its clinical trials. Notably, the shareholding of the founders has dropped below 20%, leading to the termination of their Relationship Agreement. Hemogenyx aims to enhance treatments for severe blood diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) reported that Financial Controller Andrew Wright acquired 1,088,120 ordinary shares at an average price of 1.8288 pence per share, totaling £19,899.54. This purchase increases Wright's holding to 2,715,111 shares, approximately 0.50% of the company's issued capital. The transaction, disclosed under Market Abuse Regulation, occurred on May 18, 2021, on the London Stock Exchange. The company emphasizes compliance with regulations regarding insider information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals has announced the termination of its agreement with Mint Capital regarding the £8.1 million convertible loan notes issued on February 3, 2021. The company will redeem £1.6 million of these notes, while Mint Capital will sell £6.5 million worth to investors, who will convert them into ordinary shares at 1.5 pence each. Following the conversion, no convertible loan notes will remain outstanding, allowing Hemogenyx to focus on advancing its clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Hemogenyx Pharmaceuticals has announced the conversion of £500,000 in principal amount of Convertible Loan Notes, resulting in the issuance of 22,222,222 new ordinary shares at a conversion price of £0.0225 per share. This is set to take effect on May 17, 2021, with the total number of voting shares rising to 546,415,988 post-admission. The company has no immediate plans for further drawdowns from this Convertible Notes Facility. The new shares will share the same voting rights as existing shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF)?

The current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF) is $0.04 as of August 5, 2024.

What is the market cap of HEMOGENYX PHARMACEUTICALS (HOPHF)?

The market cap of HEMOGENYX PHARMACEUTICALS (HOPHF) is approximately 22.9M.

What is Hemogenyx Pharmaceuticals focused on?

The company is focused on developing new therapies and treatments for blood diseases.

What is the significance of the Chimeric Bait Receptor platform?

The platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors.

How does Hemogenyx Pharmaceuticals expedite its R&D efforts?

The company utilizes Artificial Intelligence for protein structure simulations and in-house mRNA synthesis.

What recent FDA development has Hemogenyx Pharmaceuticals achieved?

The FDA has consented to Phase I trials of HEMO-CAR-T for AML, marking progress towards potentially life-saving treatments.

HEMOGENYX PHARMACEUTICALS

OTC:HOPHF

HOPHF Rankings

HOPHF Stock Data

22.93M
1.25B
10.27%
0.79%
Biotechnology
Healthcare
Link
United States of America
London